

National Life Building, North, FL2
Montpelier, VT 05620-3402

Tel: (802) 828-1505
Fax: (802) 828-2368

www.sec.state.vt.us



Deborah L. Markowitz
Secretary of State

William A. Dalton
Deputy Secretary

Christopher D. Winters
Director, Professional Regulation

State of Vermont
Office of the Secretary of State
Professional Regulation
Addition to Vermont Optometric Formulary
February 4, 2009


The Director of the Office of Professional Regulation has received from the Board of Optometry a request to add two drugs, Oral Minocycline and Oral Erythromycin, to the formulary.

Pursuant to the protocol for implementing changes to the Formulary for Prescription Medications for Optometrists, the Director forwarded this proposal to 1) the Department of Ophthalmology at the University of Vermont School of Medicine, 2) the Department of Pharmacology at the University of Vermont School of Medicine, and 3) the Commissioner of Health, through Donald Swartz, M.D. for comment.

More than 60 days has elapsed, and no negative comments regarding this addition to the formulary have been received.

After review the Director has determined that a change to the formulary is necessary and appropriate. The drugs listed above can be used safely by optometrists for treatment of the eye and adnexa, given the optometrists' training and education; the drug's likely utilization frequency and any existing alternatives; and the drug's systemic and other potential risks.

Therefore, effective this date, the formulary is amended to add Oral Minocycline and Oral Erythromycin.



Christopher D. Winters,
Director, Office of Professional Regulation

**Summary of Reports of the Formulary Committee
and Director of the Office of Professional Regulation**

last update: February 4, 2009

Pursuant to 26 V.S.A. § 1724 the Vermont Formulary Committee has received the request from the Board of Optometry for approval of certain classes of drugs.

In response to that request the Committee announces the following:

Drugs Not Approved:

The Formulary Committee does not approve use of “**all oral immunosuppressive agents.**” Use of any oral immunosuppressive agent is **prohibited** without specific Committee approval.

The Formulary Committee does not approve use of “**all oral antifungals**” Use of any oral antifungal is **prohibited** without specific Committee approval.

Explanation of Approval:

The Formulary Committee approves the drugs or classes of drugs listed below. The Formulary Committee’s approval is *not* a blanket approval of the use of these drugs.

Use of the drugs listed below is permitted only for the appropriate diagnosis, management, and treatment of the eye and adnexa. Any other use violates the Formulary Committee’s approval. The Committee understands that any other use can be considered and prosecuted as unprofessional conduct.

Approval is a recognition that the drugs listed may be used appropriately by trained professionals. The presence of any drug or variety of drugs on this list does not in any way relieve licensees from their duty to exercise professional judgment in the selection and proper use of these drugs.

Drugs Approved:

March 9, 2005:

- **For treatment of Glaucoma:** All oral or topical pharmaceuticals used in the treatment of glaucoma are approved.

- All topical pharmaceutical agents for the appropriate diagnosis, management, and treatment of the eye and adnexa.

March 17, 2005:

- All oral carbonic anhydrase inhibitors

- Injectables: only for the appropriate emergency stabilization of a patient in anaphylaxis
- All oral hyperosmotic agents, including but not limited to Glycerin and Isosorbide
- All non-legend, over-the-counter agents
- Specific antiherpetic agents: Acyclovir, Valacyclovir, and Famcyclovir

March 30, 2005:

- Schedule V drugs
- Schedule IV drugs
- Schedule III: Tylenol with codeine

April 13, 2005:

oral antibacterials:

- augmentin (amoxicillin/clavulanate)
- keflex (cephalexin)
- ceclor (cefaclor)
- zithromax (azithromycin)
- tetracycline
- doxycycline

May 4, 2005:

- dicloxacillin
- cloxacillin
- cipro
- levaquin

June 1, 2005:

- Allegra
- Zyrtec
- Compazine
- Zofran
- Ketoprofen
- Ibuprofen
- Naproxen
- Tramadol (Ultram)

June 22, 2005

•oral cortical steroids: approved for use up to 14 days. Any oral cortical steroid use after 14 days may occur only after consultation and or notification with the patient's primary care physician.

Approval by Director of OPR pursuant to Protocol

<http://vtprofessionals.org/opr1/optometrists/forms/protocolformodifyingformula.pdf>

Approval note: The Director's approval is *not* a blanket approval of the use of these drugs.

Use of the drugs listed below is permitted only for the appropriate diagnosis, management, and treatment of the eye and adnexa. Any other use violates the Director's approval. Any

other use can be considered and prosecuted as unprofessional conduct.

January 23, 2009

Approved drugs:

- Oral Minocycline
 - Oral Erythromycin
-